论文部分内容阅读
目的观察唑来膦酸联合化疗治疗多发性骨髓瘤(MM)骨病的疗效和不良反应。方法选择确诊的MM 34例,随机分为两组,联合化疗组为唑来膦酸+沙利度胺+MP方案;对照组只给予沙利度胺+MP方案化疗,3个疗程后比较患者骨痛缓解率,评价其疗效,并检查骨X线或骨ECT观察骨病灶范围减少状况。结果联合化疗组16例骨痛显效5例+有效9例,总有效率87.5%,明显高于对照组(P<0.05);联合化疗组影像学检查发现有7例见新骨形成,骨病灶范围不同程度减少,且不良反应轻微。结论唑来膦酸治疗多发性骨髓瘤骨痛疗效确切,不良反应小,值得临床应用。
Objective To observe the efficacy and adverse reactions of zoledronic acid combined with chemotherapy in the treatment of multiple myeloma (MM). Methods 34 cases of MM were selected and randomly divided into two groups. The combination chemotherapy group was zoledronic acid + thalidomide + MP regimen. The control group was given thalidomide + MP regimen only. After 3 courses of treatment, Bone pain relief rate, evaluation of its efficacy, and check the bone X-ray or bone ECT observed bone lesion reduced. Results In the combined chemotherapy group, 16 cases were markedly effective in 5 cases of bone pain and 9 cases were effective, the total effective rate was 87.5%, which was significantly higher than that of the control group (P <0.05). In the combined chemotherapy group, 7 cases showed new bone formation, Range to varying degrees, and minor adverse reactions. Conclusion Zoledronic acid treatment of multiple myeloma bone pain efficacy, adverse reactions, it is worth clinical application.